| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| LEVONORGESTREL (is an active metabolite)
| LEVONORGESTREL |
GENITO | ORAL IMPLANTATION INTRAUTERINE TRANSDERMAL | Cmax 8.9 NANOMOLAR Tmax 1.6 HOUR F 100 PERCENT VD 172.9 LITER (65 KILOGRAM) PPB 97 PERCENT Cl 3.4 LITER / HOUR (65 KILOGRAM) HT 36.4 HOUR | PROGESTERONE RECEPTOR PDB 3D90 (CRYSTAL STRUCTURE OF THE HUMAN PROGESTERONE RECEPTOR LIGAND-BINDING DOMAIN BOUND TO LEVONORGESTREL) LIGAND CODE = NOG (link to the list of PDB complexes) Download experimental 3D coordinates of NOG with added hydrogens | PROGESTERONE RECEPTOR AGONIST CHEMBL208 PROGESTERONE RECEPTOR P06401 PROGESTERONE RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C3 | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| NORELGESTROMIN (is an active metabolite)
| NORELGESTROMIN | GENITO | TRANSDERMAL | Cmax 2.8 NANOMOLAR Tmax 2 HOUR PPB 97 PERCENT HT 32.1 HOUR | PROGESTERONE RECEPTOR | PROGESTERONE RECEPTOR AGONIST CHEMBL208 PROGESTERONE RECEPTOR P06401 PROGESTERONE RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C3 | EMA | |||
| 3 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| NORGESTIMATE (has an active metabolite)
| NORGESTIMATE |
GENITO | ORAL | PROGESTERONE RECEPTOR ANDROGEN RECEPTOR | PROGESTERONE RECEPTOR AGONIST CHEMBL208 PROGESTERONE RECEPTOR P06401 PROGESTERONE RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C3 | EMA | ||||
| 4 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| NORGESTREL (is an active metabolite)
| NORGESTREL |
GENITO | ORAL | Cmax 8.9 NANOMOLAR PPB 97 PERCENT HT 36.4 HOUR SOLUBILITY INSOLUBLE IN WATER | PROGESTERONE RECEPTOR | PROGESTERONE RECEPTOR AGONIST CHEMBL208 PROGESTERONE RECEPTOR P06401 PROGESTERONE RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C3 | EMA | |||
